Live Breaking News & Updates on Longer Treatment Duration May|Page 1

Stay updated with breaking news from Longer treatment duration may. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aeglea BioTherapeutics : Costs Associated with Exit/Disposal - Form 8-K

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to. | April 12, 2023 ....

United States , Michaelc Hanley , Kelly Boothe , Cortney Caudill , Linda Neuman , Aeglea Biotherapeutics , Jeffrey Goldberg , Exchange Commission , European Medicines Agency , Wedbush Securities Inc , Investor Relations Corporate Communications , Aeglea Biotherapeutics Inc , Company Annual Report On Form , Ongoing Phase , Classical Homocystinuria , Begins Process , Explore Strategic , Dose Dependent Reduction , Total Homocysteine , Additional Dose Exploration , Longer Treatment Duration May , Percent Change , Baseline After , Pegtarviliase Treatment , Post Dose , Wedbush Securities ,

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives

Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels
Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May. | April 12, 2023 ....

United States , Linda Neuman , Aeglea Biotherapeutics , Jeffrey Goldberg , Cortney Caudill , Michaelc Hanley , Aeglea Biotherapeutics Inc , Exchange Commission , Wedbush Securities Inc , Company Annual Report On Form , European Medicines Agency , Dose Dependent Reduction , Total Homocysteine Levels , Additional Dose Exploration , Longer Treatment Duration May , Percent Change , Total Homocysteine , Baseline After , Post Dose , Explore Strategic , Wedbush Securities , Middle East , Immedica Pharma , Marketing Authorization Application , Classical Homocystinuria , Drug Designation ,